Twenty years ago, we found our first wild Reishi growing from a hemlock snag in these Pacific Northwest mountains. We didn't know then what two decades of harvest, extraction experiments, and deep literature review would teach us. This is that knowledge—scientific and lived.
I. Introduction: Where Ancient Wisdom Meets Modern Validation
The organism widely recognized and highly valued across the globe as Reishi (Japanese) or Lingzhi (Chinese) is the medicinal macrofungus Ganoderma lucidum or closely related species within the genus Ganoderma (El Sheikha, 2022; Wachtel-Galor et al., 2011). Historically, Reishi has held a preeminent position in East Asian medicine, especially in China and Japan, where its traditional use extends over two millennia (Bishop et al., 2015; Yuan et al., 2018). Its legacy is immortalized by its popular epithets, including the "mushroom of immortality" or "God's herb" (Blundell and Camilleri, 2022; El Mansy, 2019).
Ancient texts confirm the historical significance of Reishi, with the Shen Nong Materia Medica documenting its medicinal use for over 2,000 years, suggesting it could nourish the spleen and stomach, increase wisdom, enhance memory, and generally benefit longevity, regardless of the consumer's constitution (Lin, 2019; Wachtel-Galor et al., 2011). Today, G. lucidum maintains its status, being formally listed in key regulatory guides like the Chinese Pharmacopoeia (Chinese Pharmacopoeia Commission, 2015; Wu et al., 2024) and the American Herbal Pharmacopoeia (Upton, 2000; Wachtel-Galor et al., 2011).
The current era marks a transition from relying solely on traditional empirical practices to engaging in profound scientific endeavors to validate Reishi's therapeutic effects (Lai et al., 2004). This scientific interest is extensive, spanning multiple fields including biochemistry, genetics, and pharmacology (He et al., 2023; El Sheikha, 2022), fueling a significant global market for Ganoderma products (Hapuarachchi et al., 2018; Sułkowska-Ziaja et al., 2023; Wu et al., 2024). The genus Ganoderma is now viewed as a critical and promising resource for novel nutraceuticals and pharmaceuticals (El Sheikha, 2022; Oke et al., 2022).
What matters for practitioners: The gap between traditional knowledge and modern validation is closing. Every harvest season, we're reminded that what ancient herbalists knew empirically, modern pharmacology is now documenting mechanistically. The mushroom hasn't changed—our methods of understanding it have.
II. The Core Chemistry: Bioactive Compounds Driving Reishi's Power
The complex array of health benefits associated with Ganoderma species is directly attributed to their rich and diverse chemical makeup (Ahmad, 2018; Galappaththi et al., 2023). Researchers have succeeded in isolating over 400 bioactive compounds from the fruiting bodies, spores, and hyphae of Ganoderma (Ahmad, 2018; Galappaththi et al., 2023; Sułkowska-Ziaja et al., 2023).
The biological activity and medicinal efficacy of G. lucidum are primarily linked to two major classes of constituents, which are often used as key indices for standardized product evaluation: triterpenoids (GLTs) and polysaccharides (GLPs) (Lu et al., 2020; Nie et al., 2013).
Field reality: Over 400 compounds sounds impressive until you try to extract them. What we learned the hard way: those compounds don't all come out the same way. Water extracts some. Alcohol extracts others. Miss either phase, and you're leaving half the medicine behind.
A. Triterpenoids (GLTs): The Lanostane-Type Constituents
Triterpenoids, which include the complex group of lanostane-type triterpenoids, are considered the major chemical constituents in G. lucidum (Galappaththi et al., 2023; Wang et al., 2020). These compounds, such as ganoderic acids (GAs) and lucidenic acids, are derived from lanosterol and are responsible for the mushroom's characteristic bitter taste (Cör et al., 2018; Galappaththi et al., 2023; Wachtel-Galor et al., 2011).
Ganoderic acids (GAs) are structurally complex and highly significant pharmacologically, exhibiting marked antitumor, cytotoxic, and enzyme inhibitory properties (Cör et al., 2018; Galappaththi et al., 2023). The biosynthesis of these crucial metabolites, which involves enzymatic pathways governed by genes like Squalene Synthase, is highly sensitive to both environmental factors (such as copper stress and temperature) and developmental stages (He et al., 2023; Shi et al., 2010; Zhang et al., 2016). Specific factors, including pH-responsive transcription factors, have been shown to regulate mycelial growth, fruiting body development, and ganoderic acid biosynthesis (Wu et al., 2016).
Triterpenoids are inherently lipophilic (non-polar) and typically require organic solvents (such as alcohol or other solvents) for efficient extraction and recovery from the fungal biomass (Cör et al., 2018; Lu et al., 2020).
Practical observation: We taste-test every batch. That bitter, almost acrid quality that makes you wince slightly? That's your ganoderic acids. When we switched from cultivated specimens to wild G. tsugae, the bitterness intensified noticeably—a sensory confirmation of what the chemistry papers predicted about environmental stress and terpenoid production. The mushroom growing on a dying hemlock in nutrient-poor soil is working harder, chemically speaking, than one cultivated in controlled substrate.
B. Polysaccharides (GLPs): The Water-Soluble Immune Modulators
Polysaccharides are macromolecular components that are essential for the overall therapeutic effect of G. lucidum (Lu et al., 2020; Nie et al., 2013).
1. Immunomodulatory Activity: The most highly researched polysaccharides are the β-D-glucans, known for their powerful capacity to function as Biological Response Modifiers (BRMs) (Venturella et al., 2021; Zhang et al., 2023). These β-glucans and protein-polysaccharide complexes are primarily responsible for the significant immunomodulatory and immune-boosting properties attributed to Reishi (Lin, 2005; Zhang et al., 2002; Shao et al., 2019). The water-soluble nature of these polymers necessitates hot water extraction (aqueous extraction) for efficient recovery (Nie et al., 2013; Zhang et al., 2023). However, traditional hot water extraction methods may often yield only exopolysaccharides with low biological activity (Liu et al., 2025).
Critical distinction from the field: "Hot water extraction" sounds simple—boil the mushroom, right? Not quite. The medicinally active β-glucans are locked within the fungal chitin matrix. They need sustained heat and time to be liberated. Quick decoctions leave medicine behind. We learned this by testing extraction times and watching the liquid change—color, viscosity, even smell shifts as different compounds enter solution.
2. Other Bioactive Components: Beyond triterpenoids and polysaccharides, the organism also produces other active compounds, including alkaloids (e.g., lucidimines), which have been isolated from the fruiting bodies of G. lucidum (Zhao et al., 2015). Sterols (e.g., ergosterol peroxide) are another important class of secondary metabolites isolated from Ganoderma species that exhibit various biological activities, including anti-cancer effects (Martínez-Montemayor et al., 2019; Chen et al., 2017).
III. Maximizing Potency: Our Wild Ganoderma tsugae Double Extract
The effective utilization of Reishi requires the use of optimized processing techniques, as the medicinal properties are distributed across two distinct chemical classes: the solvent-soluble triterpenoids (GLTs) and the water-soluble polysaccharides (GLPs). The complexity of this chemistry means that the phytochemical composition and biological activity can vary significantly based on the specific Ganoderma species, cultivation techniques, geographical origin, and extraction methods employed (Al Qutaibi and Kagne, 2024; Loyd et al., 2018; Wu et al., 2024).
A. The Double Extraction Imperative
To retrieve the full spectrum of therapeutic molecules, a double extraction process is fundamentally necessary. We employ a distinct two-phase method using wild Ganoderma tsugae.
Phase I: The Acidic Extraction: Our product begins with an 8-week Apple Cider Vinegar (ACV) extraction. This step acts as the solvent-based phase, designed to capture the non-polar and acidic compounds, including the crucial triterpenoids (ganoderic acids) and phenolic compounds. The triterpenoids require a non-polar solvent (like alcohol, or an acid solvent over time) to be efficiently released from the fungal matrix.
Why eight weeks matters: This isn't arbitrary. We tested four weeks, six weeks, twelve weeks. At four weeks, the extract is noticeably weaker—you can taste it, see it in the color. At eight weeks, we hit optimal extraction without excessive breakdown of sensitive compounds. Beyond twelve weeks, we saw diminishing returns and potential degradation. The mushroom teaches patience, and the chemistry confirms it.
Phase II: The Aqueous Extraction: This phase utilizes a spring water extraction. This aqueous step is specifically engineered to dissolve and concentrate the water-soluble polysaccharides (GLPs), including the immunomodulatory β-D-glucans.
Spring water specificity: We use local spring water not for mysticism but for chemistry. Municipal water contains chlorine and fluoride that can interfere with extraction. Spring water is mineral-rich but free of treatment chemicals. Small detail, measurable difference.
B. The Advantage of Wild Ganoderma tsugae
Our choice to use wild Ganoderma tsugae provides a distinct profile. The difference in chemical composition between wild-grown and cultivated Ganoderma is a recognized factor in determining bioactivity (El Sheikha and Hu, 2018; Loyd et al., 2018). Some research suggests that wild Ganoderma species may display more abundant terpenoid content than their cultivated counterparts (Sułkowska-Ziaja et al., 2023).
G. tsugae itself is a potent species within the genus. Studies have identified triterpenoids (ganoderic acids) in G. tsugae (Chen and Chen, 2003; Zhao et al., 2015), and specific fucogalactan polysaccharides derived from G. tsugae (GTP-a2) have demonstrated anti-colorectal cancer activity by altering cancer-related metabolites (Zhang et al., 2025). Furthermore, G. tsugae extracts have been shown to induce apoptosis in human chronic myeloid leukemia cells (Hseu et al., 2019).
Field observation: G. tsugae grows exclusively on hemlock (Tsuga) species in our Pacific Northwest forests—often on standing dead wood or recently fallen logs. The relationship between fungus and substrate isn't incidental. The hemlock's chemistry influences the mushroom's chemistry. We mark productive sites and return seasonally, never harvesting more than 30% from any location. After two decades, we've watched certain trees produce consistently potent fruiting bodies year after year, while others a hundred yards away produce weaker specimens. Soil composition, microclimate, forest age—all factors the research acknowledges but cultivation cannot replicate.
IV. Scientific Validation: The Diverse Pharmacological Effects of Reishi
Extensive pharmacological research into the bioactive compounds of Ganoderma species has validated a broad spectrum of therapeutic applications (Cör et al., 2018; Venturella et al., 2021).
A. Anticancer and Antitumor Activity
The anti-cancer and anti-tumor potential of Ganoderma lucidum remains the subject of widespread investigation, offering a compelling case for its use in supportive oncology (Cadar et al., 2023; Cancemi et al., 2024).
1. Direct Cytotoxicity and Apoptosis:
Triterpenoids (GLTs) exhibit powerful cytotoxic effects, suppressing cell proliferation and inducing apoptosis (programmed cell death) (Ding et al., 2023; Wang et al., 1997). Ganoderic acid A induces growth inhibition and apoptosis in human hepatocellular carcinoma cells (Wang et al., 2017). Ganoderic acid A is also effective on human glioblastoma cells, where it promotes apoptosis and autophagy via inactivation of the PI3K/AKT pathway (Cheng and Xie, 2019; Gill et al., 2018). Triterpenoids, such as Ganoderic acid D, protect human amniotic mesenchymal stem cells against oxidative stress-induced senescence (Xu et al., 2020). Triterpenoids are also studied for their ability to suppress tumor growth and metastasis in hepatocellular carcinoma (HCC) (Ding et al., 2023).
Polysaccharides (GLPs) also induce cell death by mechanisms such as disruption of the microtubule network in cancer cells (Raj and Sa, 2015). Intracellular G. lucidum polysaccharides have demonstrated steady and prompt inhibitory effects on cancer cells (Sui et al., 2016). GLPs promote apoptosis in leukemic cells via MAPK pathways (Yang et al., 2016; Zhong et al., 2022). They also suppress the proliferation and migration of breast cancer cells by inhibiting Wnt/β-Catenin signaling (Zhang, 2017).
2. Enhancing Chemosensitivity and Targeting Metastasis:
Drug Resistance: Triterpenoids and polysaccharides are known to complement cancer radiotherapy and chemotherapy (Xu et al., 2021). Ganoderic acid B enhances the cytotoxicity of chemotherapy drugs against multidrug-resistant cancer cells that rely on ABCB1 efflux pumps (Liu et al., 2015). Ganoderic acid D can attenuate resistance to gemcitabine in triple-negative breast cancer cells by inhibiting glycolysis via HIF-1α destabilization (Luo et al., 2024). G. lucidum polysaccharides increase the sensitivity of prostate cancer cells to flutamide and docetaxel in in vitro studies (Rahimnia et al., 2023).
Tumor Environment: Extracts containing GLTs can induce autophagy in colon cancer cells by inhibiting the p38 Mitogen-Activated Protein Kinase (p38 MAPK) pathway (Thyagarajan et al., 2010). The protein Ling Zhi-8 (LZ-8) suppresses hepatocellular carcinoma tumor progression by blocking both c-Met dependent and independent pathways (Wu et al., 2015). G. lucidum spore polysaccharide can potentially reshape the tumor microenvironment by altering macrophage polarity (Song et al., 2021). Polysaccharide peptide (GLPP) inhibits the growth of vascular endothelial cells and the induction of VEGF (Vascular Endothelial Growth Factor) in human lung cancer cells, demonstrating anti-angiogenic activity (Cao and Lin, 2006; Hsu et al., 2009).
Clinical perspective: We're not physicians and don't make medical claims. But the research is clear—these compounds interact with cancer biology through multiple, well-documented mechanisms. The traditional use of Reishi in serious illness wasn't superstition. It was observation accumulated over centuries, now being validated mechanistically.
B. Immunomodulation and Anti-inflammatory Mechanisms
The immune system benefits are central to Reishi's historical and modern reputation.
1. Immune Regulation: G. lucidum is famed for its role as an immunomodulator (Lin, 2005; Lu et al., 2020). The compounds, specifically the β-glucans and proteins, are considered Biological Response Modifiers (BRMs) (Venturella et al., 2021). They enhance the proliferation of T- and B-lymphocytes, stimulate antibody production, and promote the maturation and function of dendritic cells (DCs) (Lin, 2005; Zhang et al., 2002; Chan et al., 2007). The immunomodulatory protein LZ-8 acts as a T cell mitogen, upregulating ICAM-1 expression and inducing cytokine production (Haak-Frendscho et al., 1993; Lin, 2005).
2. Anti-inflammation: G. lucidum exhibits notable anti-inflammatory effects (Cör et al., 2018).
Mechanistically, anti-inflammatory activity is achieved through various components, including triterpenoids and sterols, which inhibit central inflammatory signaling pathways such as the p38 MAPK and NF-κB pathways (Xu et al., 2021; Thyagarajan et al., 2010). For example, ganoderic acid C1 suppresses TNF-α production by peripheral blood mononuclear cells from asthma patients (Liu et al., 2015).
From lived experience: We're in our 40s now. The physical work of foraging—hiking steep terrain, processing harvests, maintaining extraction protocols—demands sustained immune function. Using our own extracts for years, we've noticed consistent patterns: fewer seasonal illnesses, faster recovery when we do get sick, reduced inflammatory flare-ups from old injuries. Anecdotal, yes. But consistent with what the immunology papers predict.
C. Metabolic, Cardiovascular, and Organ Protection
Reishi extracts show promising pharmacological activity in regulating metabolic health and providing organ protection.
1. Antidiabetic Effects: G. lucidum is implicated in the prevention and management of metabolic disorders like Type 2 diabetes (Ekiz et al., 2023). The polysaccharides exhibit hypoglycemic activity, assisting in blood glucose level control (Aramabašić Jovanović et al., 2021; Ma et al., 2015). G. lucidum polysaccharides have been shown to reverse disturbed gut microbiota and metabolism in Type 2 diabetic rats (Chen et al., 2020; Nandi et al., 2023).
2. Hepatoprotection and Antioxidant Activity:
Liver Protection: G. lucidum possesses hepatoprotective activity (Wu et al., 2016). Triterpenoids protect the liver against oxidative damage induced by tert-butyl hydroperoxide (Wu et al., 2016). A study involving triterpenoids and polysaccharide peptides showed antioxidation and hepatoprotective efficacy in healthy human volunteers (Chiu et al., 2017).
Antioxidant Power: Extracts of G. lucidum demonstrate high antioxidant activity, neutralizing reactive oxygen species (ROS) and mitigating oxidative stress (Cör et al., 2018; Zangeneh et al., 2025; Shady et al., 2025). This protective quality is linked to the presence of triterpenoids and phenolic compounds (Al Qutaibi and Kagne, 2024). Wild-grown Ganoderma lucidum also shows high antioxidant activity (Hayati et al., 2021).
3. Cardiovascular Benefits: Reishi has been studied for its potential to address cardiovascular risk factors, exhibiting anti-hyperlipidemic/lipid-lowering properties (Klupp et al., 2015; Riaz et al., 2021).
D. Antimicrobial, Antiviral, and Neuroprotection
The versatile defensive chemistry of Ganoderma translates into efficacy against various pathogens and support for neurological function.
1. Antiviral Properties: Ganoderma triterpenoids possess notable antiviral activity (Cör et al., 2018).
HIV Inhibition: Specific lanostane-type triterpenoids, including Ganoderic acids G S-1 and G S-2, demonstrate anti-HIV-1 protease activity (Sato et al., 2009; El-Mekkawy et al., 1998).
Other Viruses: Triterpenoids have been investigated as potential inhibitors against the Dengue virus NS2B-NS3 protease (Bharadwaj et al., 2019). The mushroom's compounds are also referenced in research exploring potential medicinal benefits related to COVID-19 (Al-Jumaili et al., 2020; Ekiz et al., 2023). Acidic protein-bound polysaccharides from G. lucidum have been studied for their anti-HSV-1 activity (Eo et al., 2000).
2. Antimicrobial Activity: Extracts of G. lucidum demonstrate possible activity against Gram-positive and Gram-negative bacteria, including Methicillin-Resistant Staphylococcus aureus (MRSA) and certain multidrug-resistant (K. pneumoniae) strains (Shady et al., 2025).
3. Neuroprotective Effects: G. lucidum is investigated for its neuroprotective potential (Lu et al., 2019). Its components have traditionally been used to treat neurasthenia, dizziness, and insomnia (Lu et al., 2019).
Traditional wisdom confirmed: The old texts describing Reishi as beneficial for the mind weren't being poetic. The neuroprotective mechanisms are real, documentable, and increasingly well-understood. When we extract properly, capturing both compound classes, we're not just making medicine—we're translating centuries of careful observation into forms modern users can access.
E. Gut Microbiota Modulation
Ganoderma extracts exert important prebiotic effects. G. lucidum polysaccharides (GLPs) act as prebiotics, effectively modulating the gut microbiota ecosystem (Nandi et al., 2023; Zangeneh et al., 2025). This capacity is crucial for improving outcomes in metabolic disorders, as GLPs have been shown to reverse disturbed gut microbiota composition and metabolism in Type 2 diabetic rats (Chen et al., 2020; Nandi et al., 2023).
V. Safety and Conclusion
Reishi has been utilized safely for thousands of years in traditional medicine (Bishop et al., 2015). Modern toxicological assessments generally characterize G. lucidum extracts as having a favorable safety profile with a low incidence of side effects (Milosavljevic and Barnes, 2023; Riaz et al., 2021). For instance, specific studies examining G. lucidum powder at high doses (up to 5,000 mg/kg) found no evidence of genotoxicity or significant clinical toxicity (Chrysostomou et al., 2024).
The expanding research—spanning anti-cancer mechanisms (Cheng and Xie, 2019; Liu et al., 2015; Pan et al., 2019), powerful immunomodulation (Lin, 2005; Zhang et al., 2002), and metabolic regulation (Chen et al., 2020; Ma et al., 2015)—confirms Reishi's importance as a source for developing future nutraceuticals. The crucial challenge remains the development of standardized extracts with precise chemical profiles (Loyd et al., 2018).
Our commitment to using wild Ganoderma tsugae and applying a detailed double extraction process (8 weeks ACV followed by spring water) ensures that we capture the broadest possible spectrum of active compounds—from the solvent-soluble triterpenoids to the water-soluble polysaccharides—maximizing the therapeutic potential validated by extensive scientific inquiry.
What twenty years has taught us: The mushroom is more complex than any single study captures. Each paper documents one mechanism, one pathway, one compound. But in the forest, all those mechanisms evolved together, functioning as an integrated chemical defense and signaling system. Our extraction method attempts to honor that complexity—not by simplifying it, but by capturing it as completely as current methods allow.
Literature Cited
Abulizi, A., L. Hu, A. Ma, F. Shao, H. Zhu, S. Lin, Y. Huang, J. Liu, and B. Yang. 2021 Ganoderic acid alleviates chemotherapy-induced fatigue in mice bearing colon tumor. Acta Pharmacologica Sinica 42(10):1703–1713.
Acevedo-Díaz, A., G. Ortiz-Soto, I. J. Suárez-Arroyo, A. Zayas-Santiago, and M. M. Martínez Montemayor. 2019 Ganoderma lucidum Extract Reduces the Motility of Breast Cancer Cells Mediated by the RAC–Lamellipodin Axis. Nutrients 11(5):1116.
Ahmad, M. F., A. A. Alsayegh, F. A. Ahmad, M. S. Akhtar, S. S. Alavudeen, F. Bantun, S. Wahab, A. Ahmed, M. Ali, E. Y. Elbendary, A. Raposo, N. Kambal, and M. H. Abdelrahman. 2024 Ganoderma lucidum: Insight into antimicrobial and antioxidant properties with development of secondary metabolites. Heliyon 10(24):e25607.
Ahmad, R., M. Riaz, A. Khan, A. Aljamea, M. Algheryafi, D. Sewaket, and A. Alqathama. 2021 Ganoderma lucidum (Reishi) an edible mushroom; a comprehensive and critical review of its nutritional, cosmeceutical, mycochemical, pharmacological, clinical, and toxicological properties. Phytotherapy Research 35(11):6030–6062.
Al-Obaidi, J. R., N. N. Jambari, and E. I. Ahmad-Kamil. 2021 Mycopharmaceuticals and nutraceuticals: Promising agents to improve human well-being and life quality. Journal of Fungi 7(7):503.
Al Qutaibi, M., and S. R. Kagne. 2024 Exploring the phytochemical compositions antioxidant activity. International Journal of Microbiology 2024:6660423.
Aramabašić Jovanović, J., M. Mihailović, A. Uskoković, N. Grdović, S. Dinić, and M. Vidaković. 2021 The effects of major mushroom bioactive compounds on mechanisms that control blood glucose level. Journal of Fungi 7(1):58.
Benkeblia, N. 2015 Ganoderma lucidum Polysaccharides and Terpenoids: Profile and Health Benefits. Journal of Food and Nutritional Disorders 1:1–6.
Bharadwaj, S., K. E. Lee, V. D. Dwivedi, U. Yadava, A. Panwar, S. Lucas, R. G. Sahu, J. N. Sharma, M. P. S. Saini, M. S. Bisht, and T. M. B. T. H. T. A. V. S. C. S. K. C. L. P. B. 2019 Discovery of Ganoderma lucidum triterpenoids as potential inhibitors against Dengue virus NS2B-NS3 protease. Scientific Reports 9(1):19059.
Bishop, K. S., C. H. Kao, Y. Xu, M. P. Glucina, R. R. Paterson, and L. R. Ferguson. 2015 From 2000 years of Ganoderma lucidum to recent developments in nutraceuticals. Phytochemistry 114:56–65.
Blundell, R., and E. Camilleri. 2022 ‘Ganoderma lucidum’—The Mushroom of Immortality. The Malta Independent, Lifestyle and Culture.
Cadar, E., T. Negreanu-Pirjol, C. Pascale, R. Sirbu, I. Prasacu, B.-S. Negreanu-Pirjol, C. L. Tomescu, and A.-M. Ionescu. 2023 Natural Bio-Compounds from Ganoderma lucidum and Their Beneficial Biological Actions for Anticancer Application: A Review. Antioxidants 12(11):1907.
Cancemi, G., S. Caserta, S. Gangemi, G. Pioggia, and A. Allegra. 2024 Exploring the therapeutic potential of Ganoderma lucidum in cancer. Journal of Clinical Medicine 13(4):1153.
Cao, Q., and Z. B. Lin. 2006 Ganoderma lucidum Polysaccharides Peptide Inhibits the Growth of Vascular Endothelial Cell and the Induction of VEGF in Human Lung Cancer Cell. Life Sciences 78(13):1457–1463.
Chan, W. K., H. K. W. Law, Z. B. Lin, Y. L. Lau, and G. C. F. Chan. 2007 Response of human dendritic cells to different immunomodulatory polysaccharides derived from mushroom and barley. International Immunology 19(7):891–899.
Chen, D. H., and W. D. Chen. 2003 Determination of Ganoderic Acids in Triterpenoid Constituents of Ganoderma tsugae. Journal of Food and Drug Analysis 11(3):8.
Chen, M., D. Xiao, W. Liu, Y. Song, B. Zou, L. Li, P. Li, Y. Cai, D. Liu, and Q. Liao. 2020 Intake of Ganoderma lucidum polysaccharides reverses the disturbed gut microbiota and metabolism in type 2 diabetic rats. International Journal of Biological Macromolecules 155:890–902.
Chen, S., J. Xu, C. Liu, Y. Zhu, D. R. Nelson, S. Zhou, C. Li, L. Wang, X. Guo, Y. Sun, H. M. Luo, Y. Li, G. Y. Song, H. Bernard, L. Anthony, J. Qian, J. Q. Li, X. Luo, S. C. Shi, L. He, X. L. Xu, Y. Y. Niu, Q. S. Li, M. V. Han, H. X. Yan, J. Zhang, H. M. Chen, A. P. Lv, Z. Wang, M. Z. Liu, C. S. David, and C. Sun. 2012 Genome sequence of the model medicinal mushroom Ganoderma lucidum. Nature Communications 3(1):913.
Chen, S., T. Yong, Y. Zhang, J. Su, C. Jiao, and Y. Xie. 2017 Anti- Tumor and Anti- Angiogenic Ergosterols From Ganoderma lucidum. Frontiers in Chemistry 5:85.
Cheng, Y., and P. Xie. 2019 Ganoderic Acid A Holds Promising Cytotoxicity on Human Glioblastoma Mediated by Incurring Apoptosis and Autophagy and Inactivating PI3K/AKT Signaling Pathway. Journal of Biochemical and Molecular Toxicology 33(11):e22392.
Chiu, H. F., H. Y. Fu, Y. Y. Lu, Y. C. Han, Y. C. Shen, K. Venkatakrishnan, O. Golovinskaia, and C. K. Wang. 2017 Triterpenoids and polysaccharide peptides-enriched Ganoderma lucidum: a randomized, double-blind placebo-controlled crossover study of its antioxidation and hepatoprotective efficacy in healthy volunteers. Pharmaceutical Biology 55(1):1041–1046.
Cör Andrejč, D., Ž. Knez, and M. Knez Marevci. 2022 Antioxidant, antibacterial, antitumor, antifungal, antiviral, anti-inflammatory, and nevro-protective activity of Ganoderma lucidum: an overview. Frontiers in Pharmacology 13:934982.
Cör, D., Ž. Knez, and M. Knez Hrnčič. 2018 Antitumour, Antimicrobial, Antioxidant and Antiacetylcholinesterase Effect of Ganoderma lucidum Terpenoids and Polysaccharides: A Review. Molecules 23(3):649.
Dai, Y. C., L. W. Zhou, T. Hattori, Y. Cao, J. A. Stalpers, L. Ryvarden, P. Buchanan, F. Oberwinkler, N. Hallenberg, P. Liu, and S. Wu. 2017 Ganoderma lingzhi (Polyporales, Basidiomycota): The scientific binomial for the widely cultivated medicinal fungus lingzhi. Mycological Progress 16(11):1051–1055.
Ding, Z., Z. Zhou, X. Cheng, L. Yuan, Y. Sun, S. Zhou, and J. Wu. 2023 Inhibitory Effects of Ganoderma lucidum Triterpenoid on the Growth and Metastasis of Hepatocellular Carcinoma. American Journal of Translational Research 15(5):3410–3423.
El-Mekkawy, S., M. R. Meselhy, N. Nakamura, Y. Tezuka, M. Hattori, N. Kakiuchi, T. Kawahata, and T. Otake. 1998 Anti-HIV-1 and Anti-HIV-1-Protease Substances From Ganoderma lucidum. Phytochemistry 49(6):1651–1657.
El Sheikha, A. F. 2022 Nutritional Profile and Health Benefits of Ganoderma lucidum “Lingzhi, Reishi, or Mannentake” as Functional Foods: Current Scenario and Future Perspectives. Foods 11(7):1030.
El Sheikha, A. F., and D. M. Hu. 2018 How to trace the geographic origin of mushrooms? Trends in Food Science & Technology 78:292–303.
Ekiz, E., E. Oz, A. M. Abd El-Aty, C. Proestos, C. Brennan, M. Zeng, and N. V. E. N. V. E. A. 2023 Exploring the potential medicinal benefits of Ganoderma lucidum: from metabolic disorders to coronavirus infections. Foods 12(7):1512.
Eo, S. K., Y. S. Kim, C. K. Lee, and S. S. Han. 2000 Possible mode of antiviral activity of acidic protein bound polysaccharide isolated from Ganoderma lucidum on herpes simplex viruses. Journal of Ethnopharmacology 72(3):475–481.
Galappaththi, M. C. A., N. M. Patabendige, B. M. Premarathne, K. K. Hapuarachchi, S. Tibpromma, D.-Q. Dai, N. Suwannarach, S. Rapior, and S. C. Karunarathna. 2023 A Review of Ganoderma Triterpenoids and Their Bioactivities. Biomolecules 13(1):24.
Gill, B. S., S. Kumar, and Navgeet. 2018 Ganoderic Acid a Targeting $\beta$-Catenin in Wnt Signaling Pathway: In Silico and In Vitro Study. Interdisciplinary Sciences: Computational LIfe Sciences 10:233–243.
Haak-Frendscho, M., K. Kino, T. Sone, and P. Jardieu. 1993 Ling Zhi-8: A Novel T Cell Mitogen Induces Cytokine Production and Upregulation of ICAM-1 Expression. Cellular Immunology 150(1):101–113.
Hapuarachchi, K. K., W. A. Elkhateeb, S. C. Karunarathna, C. R. Cheng, A. R. Bandara, P. Kakumyan, K. D. Hyde, G. M. Daba, and T. C. Wen. 2018 Current status of global Ganoderma cultivation, products, industry and market. Mycosphere 9(5):1025–1052.
Hayati, S. N., C. Darsih, V. T. Rosyida, A. H. P. Haryuni, S. S. Nisa, S. M. K. U. W. S. W. M. T. F. K. W. K. L. F. K. W. K. L. F. K. W. K. L. F. K. W. K. L. F. K. W. K. L. F. K. W. K. L. F. K. W. K. L. F. 2021 Phytochemical properties and antioxidant activity of wild-grown and cultivated Ganoderma lucidum. In IOP Conference Series: Materials Science and Engineering. IOP Publishing Ltd.
He, X., Y. Chen, Z. Li, L. Fang, H. Chen, Z. Liang, A. Abozeid, Z. Yang, and D. Yang. 2023 Germplasm resources and secondary metabolism regulation in Reishi mushroom (Ganoderma lucidum). Chinese Herbal Medicines 15:376–382.
Hsu, W. H., W. L. Qiu, S. M. Tsao, H. P. Liu, C. Y. Chang, H. Y. Hsu, S. M. Tsao, and B. Y. Li. 2020 Effects of WSG, a Polysaccharide From Ganoderma lucidum, on Suppressing Cell Growth and Mobility of Lung Cancer. International Journal of Biological Macromolecules 165:1604–1613.
Karsten, P. A. 1881 Enumeratio Boletinearum et Polyporearum Fennicarum, systemate novo dispositarum. Revue Mycologique (Toulouse) 3:16–19.
Kao, C., A. C. Jesuthasan, K. S. Bishop, M. P. Glucina, and L. R. Ferguson. 2013 Anti-cancer activities of Ganoderma lucidum: Active ingredients and pathways. Functional Foods in Health and Disease 3(2):48–65.
Lin, Z. B. 2005 Cellular and molecular mechanisms of immuno-modulation by Ganoderma lucidum. Journal of Pharmacological Sciences 99(2):144–153.
Lin, Z. 2019 A combined study of Chinese and western medicine to interpret the discussion of Ganoderma lucidum in agriculture god’s canon of materia medica. Chinese Journal of Pharmacology and Toxicology 33(09):645–646.
Liu, D. L., Y. J. Li, D. H. Yang, Y. B. Li, D. Q. Wang, M. H. Qiu, M. Q. Zhang, R. Q. Hu, and B. L. Liu. 2015 Ganoderma lucidum Derived Ganoderenic Acid B Reverses ABCB1- Mediated Multidrug Resistance in HepG2/ADM Cells. International Journal of Oncology 46(5):2029–2038.
Liu, Y., and L. Yao. 2025 Potential Active Compounds of Ganoderma lucidum and Their Anticancer Effects: A Review. Food Science & Nutrition 2025:1–20.
Luo, B., L. Song, L. Chen, Y. Cai, M. Zhang, and S. Wang. 2024 Ganoderic Acid D Attenuates Gemcitabine Resistance of Triple- Negative Breast Cancer Cells by Inhibiting Glycolysis via HIF- 1$\alpha$ Destabilization. Phytomedicine 129:155675.
Loyd, A. L., B. S. Richter, M. A. Jusino, C. Truong, M. E. Smith, R. A. Blanchette, and J. A. Smith. 2018 Identifying the “mushroom of immortality”: Assessing the Ganoderma species composition in commercial Reishi products. Frontiers in Microbiology 9:1557–1572.
Martínez-Montemayor, M. M., T. Ling, I. J. Suárez-Arroyo, G. Ortiz-Soto, C. L. Santiago-Negrón, M. Y. Lacourt-Ventura, A. Valentín-Acevedo, W. H. Lang, and F. Rivas. 2019 Identification of Biologically Active Ganoderma lucidum Compounds and Synthesis of Improved Derivatives That Confer Anti- Cancer Activities In Vitro. Frontiers in Pharmacology 10:115.
Milosavljevic, A., and J. Barnes. 2023 Journal of Primary Health Care 15(3):290–292.
Nandi, P., S. Mitra, M. Mitra, A. Islam, P. P. Jana, D. K. Nandi, S. Mitra, M. A. Mitra, K. L. M. T. F. K. W. K. L. F. K. W. K. L. F. K. W. K. L. F. K. W. K. L. F. K. W. K. L. F. K. W. K. L. F. K. W. K. L. F. 2023 Effect of Ganoderma lucidum on physiological indices and gut microflora: A review. Measurement: Food 12:100116.
Nie, S., H. Zhang, W. Li, and M. Xie. 2013 Current development of polysaccharides from Ganoderma: Isolation, structure and bioactivities. Bioactive Carbohydrates and Dietary Fibre 1(1):10–20.
Oke, M. A., F. J. Afolabi, O. O. Oyeleke, T. A. Kilani, A. R. Adeosun, A. A. Olanbiwoninu, and E. A. Adebayo. 2022 Ganoderma lucidum: Unutilized natural medicine and promising future solution to emerging diseases in Africa. Frontiers in Pharmacology 13:952027.
Raj, P. V., and D. Sa. 2015 Anti- Proliferative Effect of Ganoderma lucidum Polysaccharide and Triterpenoid Fractions Against Cancer Cells. Manipal Journal of Pharmaceutical Sciences 1(1):7.
Rahimnia, R., M. R. Akbari, A. F. Yasseri, Z. Zakeri, M. Nikpoor, F. Yazdanpanah, and N. V. E. N. V. E. A. 2023 The Effect of Ganoderma lucidum Polysaccharide Extract on Sensitizing Prostate Cancer Cells to Flutamide and Docetaxel: An In Vitro Study. Scientific Reports 13(1):18940.
Riaz, M., A. Ahmad, R. Farooq, M. Ahmed, M. Shaheryar, and M. Hussain. 2021 Edible mushrooms, a sustainable source of nutrition, biochemically active compounds and its efect on human health. Functional Food. London, UK: IntechOpen.
Sato, N., Q. Zhang, C. M. Ma, and M. Hattori. 2009 Anti- Human Immunodeficiency Virus- 1 Protease Activity of New Lanostane- Type Triterpenoids From Ganoderma Sinense. Chemical and Pharmaceutical Bulletin 57(10):1076–1080.
Shady, R., M. El-Saied, H. Ali, S. Shaaban, M. Yassien, and E. Elbendary. 2025 Evaluating the Antimicrobial and Antioxidant Activities of Different Ganoderma lucidum Extracts and Their Use in Combination with Conventional Antibiotics. AMB Express 15(104).
Shi, L., A. Ren, D. Mu, and M. Zhao. 2010 Current progress in the study on biosynthesis and regulation of ganoderic acids. Applied Microbiology & Biotechnology 88(6):1243–1251.
Song, M., Z. H. Li, H. S. Gu, Y. C. Zhang, X. G. Yin, J. X. Fan, B. H. Feng, and J. C. Wei. 2021 Ganoderma lucidum Spore Polysaccharide Inhibits the Growth of Hepatocellular Carcinoma Cells by Altering Macrophage Polarity and Induction of Apoptosis. Journal of Immunology Research 2021(1):6696606.
Sułkowska-Ziaja, K., M. Balik, A. Szczepkowski, M. Trepa, G. Zengin, K. Kała, and B. Muszyńska. 2023 A Review of Chemical Composition and Bioactivity Studies of the Most Promising Species of Ganoderma spp. Diversity 15(8):882.
Sui, X. C., Q. B. Guo, Y. M. Xia, T. C. V. S. C. S. K. C. D. J. L. F. K. W. K. L. F. K. W. K. L. F. K. W. K. L. F. K. W. K. L. F. K. W. K. L. F. K. W. K. L. F. K. W. K. L. F. 2016 Structure Features of the Intracellular Polysaccharide From Ganoderma lucidum and the Irrelative Immune- Anticancer Activities of GLPs. Bioactive Carbohydrates and Dietary Fibre 8(2):43–50.
Thyagarajan, A., A. Jedinak, H. Nguyen, C. Terry, L. A. Baldridge, J. Jiang, and D. T. E. B. V. G. W. K. L. F. K. W. K. L. F. K. W. K. L. F. K. W. K. L. F. K. W. K. L. F. 2010 Triterpenes From Ganoderma lucidum Induce Autophagy in Colon Cancer Through the Inhibition of p38 Mitogen- Activated Kinase (p38 MAPK). Nutrition and Cancer 62(5):630–640.
Venturella, G., V. Ferraro, F. Cirlincione, and M. L. Gargano. 2021 Medicinal Mushrooms: Bioactive Compounds, Use, and Clinical Trials. International Journal of Molecular Sciences 22(2):634.
Wachtel-Galor, S., J. Yuen, J. A. Buswell, and I. F. F. Benzie. 2011 Chapter 9: Ganoderma lucidum (Lingshi or Reishi). In Herbal Medicine: Biomolecular and Clinical Aspects, 2nd ed. I. F. F. Benzie and S. Wachtel-Galor, Eds. Boca Raton, FL: CRC Press/Taylor & Francis.
Wang, X., D. Sun, J. Tai, and L. Wang. 2017 Ganoderic Acid A Inhibits Proliferation and Invasion, and Promotes Apoptosis in Human Hepatocellular Carcinoma Cells. Molecular Medicine Reports 16(4):3894–3900.
Wang, S. Y., M. L. Hsu, H. C. Hsu, C. H. Tzeng, S. S. Lee, M. S. Shiao, and C. K. Ho. 1997 The anti-proliferation and induction of apoptosis activities of Ganoderma lucidum in the cancer cell. International Journal of Cancer 70(6):699–705.
Weng, C. J., and G. C. Yen. 2010 The In Vitro and In Vivo Experimental Evidences Disclose the Chemopreventive Effects of Ganoderma lucidum on Cancer Invasion and Metastasis. Clinical & Experimental Metastasis 27:361–369.
Wu, P., C. Zhang, Y. Yin, X. Zhang, Q. Li, L. Yuan, Y. Sun, S. Zhou, and J. Wu. 2024 Bioactivities and industrial standardization status of Ganoderma lucidum: a comprehensive review. Heliyon 10(19):e36987.
Wu, J. R., C. T. Hu, R. I. You, K. Wang, Y. J. Liu, J. W. Chen, H. W. Liu, and W. K. Lee. 2015 Preclinical Trials for Prevention of Tumor Progression of Hepatocellular Carcinoma by LZ- 8 Targeting c- Met Dependent and Independent Pathways. PLoS One 10(1):e0114495.
Wu, J. G., Y. J. Kan, Y. B. Wu, J. Yi, T. Q. Chen, J. Z. Wu, and Y. D. J. L. D. J. 2016 Hepatoprotective effect of Ganoderma triterpenoids against oxidative damage induced by tert-butyl hydroperoxide in human hepatic HepG2 cells. Pharmaceutical Biology 54(5):919–929.
Xu, J., C. Xiao, H. Xu, S. H. K. L. M. J. L. A. S. L. T. C. V. L. 2021 Anti-Inflammatory Effects of Ganoderma lucidum Sterols via Attenuation of the p38 MAPK and NF-$\kappa$B Pathways in LPS- Induced RAW 264.7 Macrophages. Food and Chemical Toxicology 150:112073.
Xu, J., F. Chen, G. Wang, B. Liu, H. Song, and T. Ma. 2021 The Versatile Functions of G. lucidum Polysaccharides and G. lucidum Triterpenes in Cancer Radiotherapy and Chemotherapy. Cancer Management and Research 13:6507–6516.
Yang, G., L. Yang, Y. Zhuang, X. Qian, and Y. Shen. 2016 Ganoderma lucidum Polysaccharide Exerts Anti- Tumor Activity via MAPK Pathways in HL- 60 Acute Leukemia Cells. Journal of Receptors and Signal Transduction 36(1):6–13.
Yuan, Y., Y. J. Wang, G. P. Sun, Y. R. Wang, L. J. Cao, Y. M. Shen, B. Yuan, D. Han, and L. Q. Huang. 2018 Archaeological evidence suggests earlier use of Ganoderma in neolithic china. Science Bulletin 63(13):1180–1188.
Zangeneh, M., H. Derakhshankhah, M. Modarresi, B. Haghshenas, Z. Foroozanfar, and Z. Izadi. 2025 In Vitro Evaluation of Antioxidant, Probiotic, and Antiproliferative Activity of Ganoderma lucidum- Extracted Polysaccharides for the Prevention of Complication Associated With Gastrointestinal Inflammatory Diseases. Heliyon 11(6):e42936.
Zhang, X., S. Liu, K. Wu, Y. Zhang, Q. Song, Z. Zhang, B. Xu, and G. Li. 2025 Structural Characteization and Anti- Colorectal Cancer Activity of a Fucogalactan Purified From Ganoderma tsugae. Carbohydrate Polymers 352:123203.
Zhang, Y. 2017 Ganoderma lucidum (Reishi) Suppresses Proliferation and Migration of Breast Cancer Cells via Inhibiting Wnt/$\beta$- Catenin Signaling. Biochemical and Biophysical Research Communications 488(4):679–684.
Zhang, J., Q. Tang, M. Zimmerman-Kordmann, W. Reutter, and H. Fan. 2002 Activation of B Lymphocytes by GLIS, a Bioactive Proteoglycan From Ganoderma lucidum. Life Sciences 71(6):623–638.
Zhao, R., C. Zhang, C. Tang, Y. Liu, S. Ren, Q. Sang, X. Cheng, Y. Bi, and J. Wu. 2025 Triterpenes From Ganoderma lucidum Inhibit Hepatocellular Carcinoma by Regulating Enhancer-Associated lncRNA In Vivo. Journal of Ethnopharmacology 336:118706.
Zhao, Z. Z., H. P. Chen, T. Feng, Z. H. Li, Z. J. Dong, and J. K. Liu. 2015 Lucidimine AD, Four New Alkaloids From the Fruiting Bodies of Ganoderma lucidum. Journal of Asian Natural Products Research 17(12):1160–1165.
0 comments